[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-acute-sequelae-of-sars-cov-2-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-acute-sequelae-of-sars-cov-2-infection":178},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,39,69,99,122,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100581441","cognitive-sensorimotor-function-in-long-covid-100581441",false,"NCT06850350","Cognitive-Sensorimotor Function in Long-COVID","Enhancing Veterans Long-COVID Care: A Cognitive-Sensorimotor Framework to Understand Gait and Balance Dysfunction","Inclusion Criteria:\n\n* Older than 18 years of age\n* Positive PCR or Rapid COVID-19 test in the past\n* Onset of COVID-19 illness greater than 3 months prior to their participation in the study\n* Self-reported ability to walk 10 meters with or without external assistance prior to COVID-19 illness\n\nExclusion Criteria:\n\n* Presence of severe cardiovascular and pulmonary disease and\u002For neurological and musculoskeletal disorders unrelated to COVID-19 (e.g., amputation, stroke, spinal cord injury)\n* Cognitive impairments precluding ability to provide informed consent.\n* Severe acute COVID-19 infection requiring hospitalization or diagnosed post-intensive care syndrome.\n* Presence of musculoskeletal, inflammatory, or neurological conditions mimicking Long COVID-19 symptoms (e.g., concussion within last 5 years, Chronic fibromyalgia, Myofascial pain syndrome, etc.)",true,"ALL","18 Years",{"count":20,"type":21},136,"ESTIMATED","OBSERVATIONAL","Growing evidence indicates that many people who have chronic post-acute sequelae of SARS-CoV-2 infection (PASC) will experience ongoing neurological and musculoskeletal impairment that can affect gait and balance. Identifying the factors contributing to these impairments and how they influence functional mobility is the first step towards creating effective evaluation and treatment protocols. In this study the investigators will examine cognition, vision, proprioception, muscle strength, gait and balance in persons with and without PASC to understand how PASC may impact functional mobility through a cognitive-sensorimotor lens. Gait and balance will be studied in environments that stress cognitive and sensory abilities. Study outcomes will be critical for the development of evidence-based Veteran Health Administration diagnostic and standard-of-care protocols to address gait and balance dysfunction in Veterans with PASC for restoring their functional mobility and independence.",[25],"Post-acute Sequelae of SARS-CoV-2 Infection","RECRUITING","2026-05-07",{"date":29,"type":30},"2026-05-08","ACTUAL",{"date":32,"type":30},"2026-04-01",{"date":34,"type":21},"2030-12-31",{"name":36,"class":37},"VA Office of Research and Development","FED",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":66,"locationsCount":38},"100509532","nc-testing-in-lc--pots-100509532","NCT05914649","NC Testing in LC & POTS","Neurocognitive Testing in Long COVID and Postural Tachycardia Syndrome Patients With Normal Saline: A Pilot Study","Inclusion Criteria:\n\n* Patients with diagnosis of Long COVID\n* SARS-COV2 test positive\n* Symptoms \\> 12 weeks post COVID\n* Subjective complaint of 'brain fog\" or cognitive dysfunction\n* Patients with diagnosis of Postural Orthostatic Syndrome (POTS) from the Calgary Autonomic Investigation and Management Clinic\n* Subjective complaint of 'brain fog\" or cognitive impairment\n* Healthy participants\n* Without POTS or \"brain fog\"\n* Age 18 to 60 years\n* Female and Male\n* Able to give an informed consent\n\nExclusion Criteria:\n\n* Patients with overt causes for POTS (e.g., dehydration, prolonged bed rest)\n* An inability to safely withdraw from medicine(s) that could make test interpretation difficult and impossible.\n* Other factors which are in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule.\n* Unable to give an informed consent.","60 Years",{"count":48,"type":21},100,"INTERVENTIONAL",[51],"NA","Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or \"Long COVID\") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).",[54,55],"Postural Orthostatic Tachycardia Syndrome","Post Acute Sequelae of SARS CoV 2 Infection",[57,58,59,60],"POTS","Long COVID","Cognitive","Brain Fog","2026-04-30",{"date":27,"type":30},{"date":64,"type":30},"2024-09-19",{"date":34,"type":21},{"name":67,"class":68},"University of Calgary","OTHER",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":38},"100538517","predictors-of-post-covid-19-clinical-and-cognitive-consequences-100538517","NCT06291870","Predictors of Post-COVID-19 Clinical and Cognitive Consequences","Predictors of Post-COVID Clinical and Cognitive Consequences","SCLC","Inclusion Criteria:\n\n* All individuals 18 years or older, with prior history of COVID-19 infection diagnosis\n* Both genders including all racial and ethnic groups\n* Patients with OSA (apnea hypopnea index of 5\u002Fhour on polysomnography) with history of COVID-19 infection will be eligible with prior history of COVID-19 infection and without COVID-19 for Aim 2\n\nExclusion Criteria:\n\n* Inability to give consent\n* Active suicidal symptoms\n* Children of all ages\n* Pregnant women",{"count":78,"type":21},200,"3 Months","The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients. These sequelae may be present four or more weeks after SARS-COV-2 infection, including patients who had initial mild or asymptomatic acute infection. However, there is complete absence of data whether chronic sleep changes due to COVID-19 infection may influence these physical and mental health consequences. While fatigue is one of the common post-COVID conditions, there are no systematic examinations of sleep disturbances in COVID-19 survivors. This will be a pilot observational retrospective and prospective cohort study, to systematically assess if sleep disturbances and severity of sleep apnea comprise a modifiable facet of PASC as well as the short-term and longer-term effects of COVID-19 infection itself on sleep, cognitive function, exercise capacity and lung function.",[55,82],"Obstructive Sleep Apnea",[84,85,86,87,88,89,90],"COVID-19","Quality of Life","Neurocognitive Function","Sleepiness","Sleep Quality","Six minute walk","Fatigue","2026-01-21",{"date":93,"type":30},"2026-01-23",{"date":95,"type":30},"2023-01-19",{"date":97,"type":21},"2026-12-31",{"name":36,"class":37},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":49,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":38},"100482780","physiology-of-long-covid-19-and-the-impact-of-cardiopulmonary-rehabilitation-on-quality-of-life-and-functional-capacity-100482780","NCT05566483","Physiology of Long COVID-19 and the Impact of Cardiopulmonary Rehabilitation on Quality-of-Life and Functional Capacity","Physiological Underpinnings of Post-Acute Sequelae of SARS CoV-2 (\"Long COVID\") and Impact of Cardiopulmonary Rehabilitation on Quality-of-Life and Functional Capacity","Inclusion Criteria:\n\n* Adults ≥18 years with documented history of COVID-19 infection and symptoms consistent with Long COVID lasting \\>12 weeks after diagnosis.\n\nExclusion Criteria:\n\n* History of cardiovascular\u002Fpulmonary disease prior to infection\n* COVID-related myocardial injury such as evidence of myocarditis\n* Deep vein thrombosis\u002Fpulmonary embolism following COVID-19 infection\n* Exercise intolerance resulting from conditions that are not related to cardiorespiratory or autonomic factors (e.g. osteoarthritis or other musculoskeletal diseases);\n* Dependency of supplemental oxygen following COVID infection due to cardiovascular and\u002For pulmonary complications following acute COVID infection",{"count":107,"type":21},30,[51],"The primary objectives of this study are to determine whether exercise training is an effective strategy for treatment of Long COVID and characterize the cardiorespiratory and autonomic physiology in these patients to precisely characterize mechanisms contributing to this syndrome.",[25],[112,58],"Cardiopulmonary Rehabilitation","2025-11-26",{"date":115,"type":30},"2025-12-04",{"date":117,"type":30},"2023-03-01",{"date":119,"type":21},"2027-10-31",{"name":121,"class":68},"University of Colorado, Denver",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":130,"enrollmentInfo":131,"targetDuration":133,"studyType":22,"phases":4,"briefSummary":134,"conditions":135,"keywords":141,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100592359","observational-study-of-intranasal-ivig-in-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-patients-undergoing-medical-tourism-100592359","NCT06992401","Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism","An Observational Study Collecting Real-World Data on Intranasal IVIG Treatment in Long COVID-19 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients With Immunodeficiency Engaged in International Medical Tourism","IVIG-LC","Inclusion Criteria:\n\n* Age 18 to 65 years\n* Clinical diagnosis of Long COVID (symptoms persisting ≥12 weeks after SARS-CoV-2 infection)\n* Laboratory-confirmed immunodeficiency, including one or more of the following:\n* Low serum IgG and\u002For IgA\n* Specific antibody deficiency\n* Low pneumonia titers\n* Elevated inflammatory markers (e.g., CRP, cytokines)\n* No active infections at the time of enrollment (bacterial, viral, or fungal)\n* Negative for Lyme disease and NMDAR antibodies\n* Willingness to provide informed consent for data collection and use\n\nExclusion Criteria:\n\n* Current or recent active infection (e.g., viral, bacterial, or fungal)\n* Use of immunosuppressive therapy within the last 3 months\n* Active infections: Participants with active infections, including viral, bacterial, or fungal infections, will be excluded\n* Neurological disorders: Participants with diagnosed neurological disorders (e.g., multiple sclerosis, Parkinson's disease, Alzheimer's disease) will be excluded\n* Immunosuppressive therapy: Participants receiving immunosuppressive therapy will be excluded\n* Inability to comply with study assessments or procedures","65 Years",{"count":132,"type":21},50,"12 Weeks","This observational study is being conducted by Healing Hope International to collect real-world data on an emerging treatment approach for Long COVID in patients with immunodeficiency. The study investigates the effects of intranasal immunoglobulin (IVIG) therapy in a real-world setting.\n\nParticipants will be individuals diagnosed with Long COVID who have confirmed immunodeficiency, such as low IgG or IgA levels or specific antibody deficiency. These individuals are receiving care through international clinical programs and will not receive any treatment as part of this study. Instead, Healing Hope will collect health information, clinical outcomes, and laboratory results from participating sites to better understand how intranasal IVIG might help reduce symptoms such as fatigue, brain fog, inflammation, and immune dysregulation.\n\nThe goal of this study is to contribute new insights into potential treatment options for Long COVID and to support responsible, science-backed care models for patients participating in medical tourism. No experimental drugs are being administered as part of this protocol. All treatment decisions are made independently by each clinical site. Data will be anonymized and used to advance knowledge in the field of immunological recovery and neuroinflammation.",[136,58,137,138,139,140],"Post-Acute Sequelae of SARS-CoV-2 Infection","Long COVID Fatigue","Long COVID Syndrome","COVID 19 Associated Coagulopathy","COVID-19 Vaccination",[142,143,144,145,146,147,148,149,150,151,152,153],"Intranasal IVIG","Real-world data","Medical tourism","Long COVID fatigue","Cytokine panel","Immunoglobulin therapy","Brain fog","Chronic inflammation","Real-world evidence","Global health","Post-viral syndrome","Immune recovery","NOT_YET_RECRUITING","2025-11-24",{"date":157,"type":30},"2025-12-02",{"date":159,"type":21},"2026-08-01",{"date":161,"type":21},"2029-07-15",{"name":163,"class":68},"Tamara C Tamas",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":49,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":38},"100562016","evaluating-immunomodulatory-interventions-in-post-acute-sequelae-of-sars-cov-2-infection-100562016","NCT06597682","Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction","A Randomized Controlled Basket Study for Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction (RISE)","RISE","Inclusion Criteria:\n\n* 1\\. Age ≥18 years;\n* 2\\. Post-infection with SARS-CoV-2 for more than 3 months and meets the World Health Organization (WHO) definition of Long COVID;\n* 3\\. Symptom criteria: Meet the inclusion and exclusion criteria for each symptom cluster;\n* 4\\. Fertile female subjects are not breastfeeding or pregnant at the time of enrollment (negative urine pregnancy test);\n* 5\\. Willing and able to provide informed consent, complete surveys, clinical assessments, and all necessary follow-up visits;\n\nSymptom Cluster Inclusion Criteria:\n\n* Inflammatory Cardiac Involvement Symptom Cluster\n* 1\\) Age: 18-75 years old;\n* 2\\) Presence of cardiac symptoms at the time of enrollment (e.g., Chest tightness after physical activity, chest pain, difficulty breathing, palpitations, fatigue, etc.);\n* 3\\) CMR shows the following abnormal findings based on any of the following criteria:\n* a) Native T1 increase ≥ 1130 milliseconds at 3.0 T (or an increase of 1030 milliseconds at 1.5 T) and\u002For;\n* b) Native T2 ≥ 39.5 milliseconds at 3.0 T (or 49.5 milliseconds at 1.5 T) and\u002For;\n* c) Presence of non-ischemic myocardial and pericardial late gadolinium enhancement and\u002For;\n* d) Left ventricular ejection fraction ≥ 40% and ≤50%.\n* Cough Symptom Cluster\n* 1\\) Clinical assessment of cough according to ACCP guidelines indicates no cough caused by other diseases such as COPD, asthma, chronic bronchitis, gastroesophageal reflux, bronchiectasis, etc.;\n* 2\\) Chest X-ray or CT scan shows no abnormalities that could lead to cough or other serious lung diseases;\n* 3\\) FENO ≥25 ppb, or the proportion of eosinophils in sputum cytology ≥2.5%; or the blood eosinophil count \\>0.3×10⁹\u002FL.\n* Fatigue Symptom Cluster\n* 1\\) Fatigue Severity Scale (FSS) average score ≥ 4;\n* 2\\) Any inflammatory marker (CRP, ESR, PCT, ferritin, IL-6, TNFα) is above the upper limit of normal.\n\nExclusion Criteria:\n\n* 1\\. Known SARS-CoV-2 infection within 3 months prior to the date of informed consent signature;\n* 2\\. Systemic fungal infection and active infections that cannot be controlled by anti-infective agents;\n* 3\\. Current or recent (within the last 10 weeks) use of glucocorticoids, other immunosuppressants, or biologic agents;\n* 4\\. Known allergy\u002Fsensitivity or any hypersensitivity reaction to the study intervention or control components;\n* 5\\. Known contraindications to the study intervention;\n* 6\\. Any persistent central nervous system disorders, psychiatric illnesses, chronic respiratory or cardiac diseases, Underlying diseases (poorly controlled diabetes, poorly controlled hypertension, peripheral edema, cataracts or glaucoma, peptic ulcer disease, femoral head necrosis, low bone density, or osteoporosis);\n* 7\\. For female participants: pregnant or breastfeeding at screening, or expecting to become pregnant during the study period; women of childbearing age who are unwilling to use effective contraceptive measures (defined as PEARL index \\\u003C1, such as birth control pills, intrauterine devices);\n* 8\\. Known alcohol, drug, or chemical abuse;\n* 9\\. Currently participating in another clinical trial;\n* 10\\. Deemed ineligible to participate in this study by the investigator's assessment.\n\nSymptom Cluster Exclusion Criteria:\n\n* Inflammatory Cardiac Involvement Symptom Cluster\n* 1\\) Past medical history or cardiac magnetic resonance (CMR) evidence indicating significant cardiac disease, including:\n* a) Known left ventricular ejection fraction (LVEF) \\\u003C40% indicating cardiac dysfunction;\n* b) Congestive heart failure (New York Heart Association Class III-IV);\n* c) Ongoing treatment for heart failure (including HFrEF and HFpEF);\n* d) Confirmed ischemic heart disease, peripheral artery disease, and\u002For cerebrovascular disease;\n* e) Persistent or permanent atrial fibrillation or significant arrhythmias;\n* f) Congenital or clinically relevant valvular heart disease (moderate or severe);\n* g) Specific cardio myopathies (hypertrophic, hypertensive heart disease, amyloidosis, previous myocarditis, non-ischemic dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, non-compacted cardiomyopathy, etc.);\n* 2\\) Contraindications for contrast-enhanced cardiac magnetic resonance (CMR) imaging, such as: use of implanted devices not compatible with MRI; known allergy to gadolinium-based contrast agents (CBGA);\n* 3\\) Patients with structural heart disease or incidental arrhythmias detected on cardiac magnetic resonance imaging will be advised to consult their physicians.\n* Cough Symptom Cluster\n* 1\\) Current smoker or having quit smoking for less than 6 months;\n* 2\\) Intolerance to pulmonary function testing and\u002For FeNO;\n* 3\\) Chest CT showing acute pulmonary infection-related diseases;\n* 4\\) Forced expiratory volume in 1 second (FEV1) \u002F Forced vital capacity (FVC) ratio less than 60%;\n* 5\\) Currently taking or having used angiotensin-converting enzyme inhibitors (ACEI) within the past 3 months of screening;\n* 6\\) Received any relevant traditional Chinese or Western medical treatment within the last month.\n* Fatigue Symptom Cluster\n* 1\\) Received any relevant traditional Chinese or Western medical treatment within the last month, taking sedatives, hypnotics, melatonin, or antidepressants;\n* 2\\) Known previous diagnosis of myalgic encephalomyelitis\u002Fchronic fatigue syndrome unrelated to SARS-CoV-2 infection;\n* 3\\) Known previous autonomic dysfunction unrelated to SARS-CoV-2 infection;\n* 4\\) Fatigue caused by metabolism-related diseases (such as hyperthyroidism or hypothyroidism, malnutrition) that developed following SARS-CoV-2 infection.","75 Years",{"count":174,"type":21},632,[51],"This study is a prospective, randomized controlled, basket trial. Patients diagnosed with Post-Acute Sequelae of SARS-CoV-2 Infection who meet the inclusion and exclusion criteria are recruited and divided into three symptom clusters: Inflammatory Cardiac involvement symptoms cluster, cough symptoms cluster and fatigue symptoms cluster. Each symptom cluster is randomly divided into an experimental group and a control group, Patients who do not accept treatment can be included in the observational cohort. Subjects in the experimental group receive immunomodulatory interventions plus conventional treatment, while subjects in the control group receive conventional treatment only. Subjects in each symptom cluster undergo clinical medical record data collection, laboratory tests, and imaging examinations at specified time points, as well as records of adverse events.",[178],"Post-acute Sequelae of SARS-COV-2 Infection",[178,58,180],"Immunomodulatory Interventions","2025-03-05",{"date":183,"type":30},"2025-03-06",{"date":185,"type":21},"2025-03",{"date":187,"type":21},"2027-07",{"name":189,"class":68},"Huashan Hospital"]